Fly News Breaks for February 14, 2020
Feb 14, 2020 | 08:44 EDT
Raymond James analyst Jayson Bedford raised his price target for DexCom to $288 from $258 and reiterated an Outperform rating rating based on beatable estimates, a best-in-class growth profile, and visibility into a TAM-expanding new product launch. The analyst says that as the fastest growing large-cap Med Tech company, Dexcom should continue to benefit from rapidly increasing awareness/adoption of CGM, with the primary market of insulin-dependent people with diabetes only ~31% penetrated in the U.S. and several adjacencies offering substantial longer-term opportunities.
News For DXCM From the Last 2 Days
There are no results for your query DXCM